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observed. Levels of PCDDs and PCDFs were highest in 
India and some European and African countries. PCB lev-
els were highest in East and West Europe. The highest lev-
els of ΣDDTs were found in less industrialized countries. A 
temporal downward trend for PCDDs, PCDFs and PCBs is 
indicated. A risk–benefit assessment indicates that human 
milk levels of PCDDs, PCDFs and PCBs are still signifi-
cantly above those considered toxicologically safe, while 
ΣDDTs are below or around those considered safe. With 
respect to potential adverse health effects, a more dominant 
role of in utero exposure versus lactational exposure is indi-
cated. If potential adverse effects are balanced against posi-
tive health aspects for (breastfed) infants, the advantages of 
breastfeeding far outweigh the possible disadvantages. Our 
observations provide a strong argument to plea for further 
global source-directed measures to reduce human exposure 
further to dioxin-like compounds.
Keywords Human milk · Dioxins · PCBs · DDT · 
Breastfeeding · Benefit–risk
Introduction
Since the mid-eighties, the World Health Organization 
(WHO) coordinates a comprehensive global monitoring 
program on polychlorinated biphenyls (PCBs), polychlo-
rinated dibenzo-p-dioxins (PCDDs) and polychlorinated 
dibenzofurans (PCDFs) (Malisch et al. 2010; Malisch and 
Van Leeuwen 2003; WHO 1989, 1996). This program 
focuses particularly on the exposure of breastfed and aims 
to identify the impact of measures taken to reduce or pre-
vent environmental exposure to these chemicals.
The Stockholm Convention on Persistent Organic Pol-
lutants (POPs) has the objective to protect human health 
Abstract Since 1987, the World Health Organization 
(WHO) carried out global surveys on polychlorinated 
dibenzo-p-dioxins (PCDDs), polychlorinated dibenzo-
furans (PCDFs) and polychlorinated biphenyls (PCBs) 
in human milk. This study presents a review of the three 
most recent surveys from 2000 to 2010, including DDT. 
The objective was to identify global quantitative differ-
ences and provide baseline information for 52 countries 
or provide time-trends for countries with previous data. 
Individual human milk samples were collected following a 
WHO-designed procedure and combined to form a national 
pooled sample. Here, we report global levels for PCDDs, 
PCDFs, PCBs and the sum of o,p′-DDT, p,p′-DDT, o,p′-
DDE, p,p′-DDE, o,p′-DDD and p,p′-DDD (ΣDDTs). A 
concise risk–benefit evaluation related to human milk con-
tamination with these persistent organic pollutants (POPs) 
was also done. Large global and regional differences were 
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and environment from POPs by reducing or eliminating 
their releases into the environment. Under this convention, 
human milk was recommended as a core matrix for bio-
monitoring. To evaluate the effectiveness of the Stockholm 
Convention, the results from these human milk surveys will 
be used as a baseline to identify possible global temporal 
trends and spatial distributions of POPs. These surveys also 
provide a suitable basis for possible source-directed reduc-
tion measures of POPs in human food and milk on a coun-
try-by-country basis.
For biomonitoring of POPs, human milk is the best 
matrix to use, because it is easily available, collecting is 
non invasive, and its high lipid content makes the extrac-
tion of POPs easy (Liem et al. 2000). PCDDs, PCDFs and 
PCBs in human milk are also a good reflection of the body 
burden, as human blood and adipose tissue concentrations 
are often (closely) similar (Needham et al. 2011; Todaka 
et al. 2010).
Experimental and epidemiological studies indicate 
that the early life stage is most sensitive for the effects of 
dioxin-like (DL) compounds and PCBs (Birnbaum and 
Tuomisto 2000; Peterson et al. 1993). Therefore, placental 
transfer and uptake via human milk can be of toxicologi-
cal significance. Consequently, the exposure of breastfed 
infants is a challenge for the benefit–risk assessment of 
human milk, because significant health benefits concur 
with possible adverse health effects of these POPs (Aliyu 
et al. 2010; Landrigan et al. 2002; Mead 2008).
This article reviews three global surveys of PCDDs, 
PCDFs, PCBs and DDT in human milk. These surveys are 
meant to identify worldwide differences of human milk 
contamination, but not meant to derive a “ranking” of 
countries with respect to risk assessment for the breastfed 
infant. Based on the global levels observed during these 
surveys, a concise benefit–risk evaluation is included for 
the breastfed infant.
Analytical aspects
The State Institute for Chemical and Veterinary Analysis of 
Food (Freiburg, Germany) analyzed the composite human 




In short, samples were collected following a protocol deal-
ing primarily with number and type of samples, donor 
selection, storage, pooling and shipping of samples. Inclu-
sion criteria for donating mothers were: (a) primiparae, 
(b) healthy, (c) exclusive breastfeeding to one child and 
(d) local resident for about 5 years. Furthermore, WHO 
requirements in conducting studies with human milk are: 
(a) breastfeeding should always be promoted and sup-
ported, (b) sampling should neither be an unnecessary bur-
den to the mother nor compromise the nutritional status of 
the infant, (c) samples should be as representative of the 
relevant population of the country as possible, (d) donor 
selection should take into account possible contributing 
factors, e.g., dietary habits and demographic differences. 
Approval from all national ethics committee was obtained.
The third survey (2000–2003) included pooled milk 
samples from at least two well-defined groups of ten 
mothers. If possible, a high- and low-exposure group was 
selected. If more than one pooled sample was donated, the 
median value was used for comparison.
For the fourth (2005–2007) and fifth (2008–2010) sur-
veys, pooled milk samples from at least 50 donors per 
country were used. The donors were considered representa-
tive for a general background situation in a specific coun-
try. The samples of individual mothers remain available for 
future analysis of other POPs.
In the third survey, 102 samples were analyzed for 
PCDDs, PCDFs, PCBs and partly for DDT. In the fourth 
and fifth survey 13 and 23 countries sent in, respectively, 
16 and 28 samples. As the fourth and fifth surveys were 
done within a relatively short time period, it was decided 
to combine the data in this study. In Figs. 1 and 2, the par-
ticipating countries for dioxin-like compounds and ΣDDTs 
are presented, while in Figs. 3, 4, 5 and 6, more detailed 
analytical data are presented for each country.     
Chemical analysis
The analytical procedure for PCDDs, PCDFs and DL-
PCBs has been described earlier (Malisch et al. 2000; 
Malisch and Dilara 2007; Malisch and Van Leeuwen 2002). 
The limit of quantification (LOQ) expressed as WHO toxic 
equivalencies (TEQs) was ~0.1 pg/g lipid. Toxic equiva-
lency factors (TEFs) for DL compounds as proposed 
by the 2005 WHO expert meeting have been used (Van 
den Berg et al. 2006). The LOQ for individual non DL-
PCBs was <0.05 ng/g lipid and for DDT, DDD and DDE 
~0.5 ng/g lipid. Concentrations of the indicator PCBs 28, 
52, 101, 138, 153 and 180 are expressed as the sum of these 
PCBs (ΣPCBs). The mono-ortho substituted PCB 118 has 
DL properties and included in the TEQ calculations.
The chemical analysis of DDT and its metabolites has 
been described earlier (Hedley et al. 2010; UNEP 2007). 
ΣDDTs concentrations were calculated after correction for 
molecular weight to provide the sum of o,p′-DDT, p,p′-
DDT, o,p′-DDE, p,p′-DDE, o,p′-DDD and p,p′-DDD.
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Global occurrence
PCDDs, PCDFs and PCBs
Third survey
The results for the third survey (2000–2003) are shown in 
Figs. 3, 4, 5 and 6. Between countries, approximately one 
order of magnitude variation was found. The lowest con-
centrations of dioxin-like compounds were predominantly 
found in less industrialized countries (Fig. 1). Compara-
tively higher levels were found in the more highly indus-
trialized European countries. Many Western and Eastern 
European countries had comparatively high levels of DL-
PCBs, with the highest observed in the Ukraine. Remark-
ably high levels of PCDDs and PCDFs were found in 
Egypt. In contrast, the levels of PCBs in Egypt were much 
lower compared to many other industrialized countries 
studied (Figs. 3, 4, 5). An almost linear relationship was 
found between PCDDs and PCDFs versus DL-PCBs that 
becomes less distinct at higher concentrations (Fig. 7a). 
For most industrialized countries, the contribution of 
PCDDs/PCDFs and DL-PCBs was approximately equal. 
The levels of indicator PCBs measured in the third sur-
vey vary widely between countries. In Europe, high lev-
els were found in, e.g., the Czech Republic and Slovakia. 
Significantly lower levels were observed in the Southern 
Hemisphere (Fig. 5). As could be expected, a strong rela-
tionship between DL-PCBs and indicator ΣPCBs was 
found (Fig. 7b).
Fourth and fifth surveys
The results of the combined fourth and fifth surveys 
(2005–2010) expressed in TEQ or ΣPCBs are also 
shown in Figs. 3, 4, 5 and 6. Many countries provided 
only one pooled sample, and no median levels could be 
established. PCDD, PCDF and PCB levels were again 
by far the highest in Europe. The levels in less indus-
trialized countries were significantly lower than those 
Fig. 1  Participating countries in the WHO/UNEP human milk global surveys and levels of dioxin-like compounds expressed in TEQs (Van den 
Berg et al. 2006)
86 Arch Toxicol (2017) 91:83–96
1 3
in Europe. This survey period confirms again that many 
countries in the Southern Hemisphere have low levels of 
PCDDs, PCDFs and PCBs (Figs. 3, 4, 5). In Africa, the 
widest variation in contamination was observed. Kenya 
and Uganda had the lowest levels of PCDDs and PCDFs, 
while Côte d’Ivoire and the Democratic Republic of the 
Congo had the highest levels in these surveys (Fig. 3). It 
is noticeable that the latter countries did not have excep-
tional high levels of PCBs (Figs. 4, 5), indicating that the 
high PCDDs and PCDFs contamination is not associated 
with PCB-related occurrence. Most Asian countries stud-
ied in these surveys had relatively low levels of PCDDs/
PCDFs and PCBs. However, exceptional high levels of 
PCDDs and PCDFs were detected in India (Fig. 2), but 
levels of PCBs in this country were not high (Figs. 4, 5). 
Limited information was obtained from the Caribbean 
and Central/South American countries, but relatively low 
levels of PCDDs, PCDFs and PCBs were found for those 
countries studied. Similar, levels in Australia were low, 
indicating limited contamination of human milk with 
these compounds (see Fig. 1).
To detect a possible downward temporal trend of 
PCDDs, PCDFs and PCBs, a country-by-country com-
parison was made for those countries that participated in 
both survey periods (Fig. 8a–c). Although the number of 
countries that could be compared is limited, these results 
may indicate that PCDD, PCDF and PCB levels in human 
milk further declined in the first decade of the twenty-first 
century.
DDT and metabolites
The highest ΣDDTs levels were found in a number of 
Asian countries and Haiti (Figs. 2, 6). The high ΣDDTs 
levels in Hong Kong SAR in the third survey are notice-
able, but a significant reduction was observed in the fifth 
survey. Surprisingly, ΣDDTs levels in Tajikistan were 
nearly a factor of three higher than in India. If the ranking 
order of ΣDDTs levels is reviewed, the tropical countries 
represent the majority of the upper half of ΣDDTs human 
milk levels. This observation certainly reflects its use in 
Fig. 2  Participating countries in the WHO/UNEP human milk global surveys and levels of ΣDDTs
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relation to the occurrence and prevention of malaria in 
these regions in recent times. In addition, it should be noted 
that no relationship was found between PCDDs, PCDFs 
and PCBs versus ΣDDTs levels, which illustrates the coun-
try-by-country differences in industrialization versus (for-
mer) malaria prevention with DDT (Fig. 7c, d).
Fig. 3  Results of the WHO/
UNEP surveys for PCDDs and 
PCDFs in TEQs (pg/g lipid) 
in pooled human milk samples 
from different countries. The 
dotted red line represents the 
calculated safe level of these 
compounds for the breastfed 
infant (color figure online)




This study is the first in its kind reviewing global tempo-
ral and spatial contamination of PCDDs, PCDFs, PCBs 
and DDT of human milk. For many developing countries, 
this is the first time that such data are evaluated in a global 
perspective. Our results show that geographical areas with 
the highest levels are mostly associated with industrializa-
tion (Figs. 1, 2). In this review, the results of the fourth and 
fifth survey were combined. With approximately 5 years in 
between, we expected no major effect on the overall con-
clusions, because of the high environmental persistence and 
slowly decreasing levels of these POPs. Many European 
countries were found in the upper half (>5 pg TEQs/g lipid) 
of the human milk levels of PCDDs and PCDFs (Fig. 3). 
Surprisingly, some less industrialized countries from Asia, 
Fig. 4  Results of the WHO/
UNEP surveys for DL-PCBs 
in TEQs (pg/g lipid) in pooled 
human milk samples from dif-
ferent countries. The dotted red 
line represents the calculated 
safe level of these compounds 
for the breastfed infant (color 
figure online)
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Africa and South America had similar high levels. In con-
trast, PCB levels in these non-European countries were 
relatively low, <100 ng/g lipid (Figs. 4, 5). Thus, PCB con-
tamination contributes little to the high levels of TEQs in 
these countries. Combustion and industrial processes more 
likely contribute to the human exposure of PCDDs and 
PCDFs (UNEP 2011). Clay consumption (geophagia) by 
pregnant women is the likely source of PCDD and PCDF 
exposure in some African countries that can lead to high 
levels in human milk (Reeuwijk et al. 2013). A downward 
trend appears to be present for DL compounds and PCBs 
during our two survey periods (Fig. 8a–c). A reduction in 
environmental levels during our surveys can be one expla-
nation. However, the lower number of European countries 
Fig. 5  Results of the WHO/
UNEP surveys for the sum of 
the indicator PCBs in ng/g lipid 
in pooled human milk samples 
from different countries. The 
dotted red line represents the 
calculated safe level of these 
compounds for the breastfed 
infant (color figure online)
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in the fourth and fifth surveys may also be responsible or 
contribute to this apparent decrease. To resolve this issue, 
time-trends should best be followed on country-by-country 
basis. This has already been done for, e.g., Germany, Nor-
way, The Netherlands, Japan and the USA, and confirms 
a downward trend (Furst et al. 1994; LaKind et al. 2001; 
Liem et al. 2000; Papke 1998). This suggests that the pos-
sible downward trend in the WHO surveys may indeed be 
real and no coincidence due to the pooled samples. The 
global distribution for ΣDDTs is almost exclusively asso-
ciated with countries where malaria is still a significant 
health problem (Fig. 2).
Fig. 6  Results of the WHO/
UNEP surveys for the sum 
of DDT-like compounds in 
μg/kg lipid in pooled human 
milk samples from different 
countries. The dotted red line 
represents the calculated safe 
level of these compounds for 
the breastfed infant (color figure 
online)
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Risks
There is an ongoing discussion regarding the benefits ver-
sus risks of breastfeeding in relation to the presence of 
POPs in human milk. The WHO has always promoted 
exclusive breastfeeding because of its positive health 
aspects for the neonate and mother, but pros and con’s 
remain. The results of this WHO/UNEP study can also be 
used to weight the benefits versus risks on a global level.
The WHO derived a Tolerable Daily and (Provisional) 
Monthly Intake (TDI or PTMI) for DL equivalents (TEQ) 
of 1–4 and 70 pg TEQ/kg bw per day or month, respec-
tively (WHO 2000, 2002). The US-EPA proposed an oral 
reference dose (RfD) of 0.7 pg TCDD/kg bw per day (US-
EPA 2010), and the ATSDR set a minimal risk level (MRL) 
for acute and semi-chronic exposure of 20 and 1 pg TCDD/
kg bw per day, respectively (ATSDR 1998). By default, 
these safety standards are meant for chronic life time expo-
sure and not applicable for the breastfeeding situation, 
which covers a much shorter time period of life. However, 
in-depth analysis of the underlying data shows that the most 
sensitive endpoints used to derive these safety standards 
often involve pre- or postnatal experimental studies. These 
effects include immune suppression, sperm count, genital 
malformation in rodents, while neurobehavioral effects are 
among the most sensitive endpoints in non-human primates 
(WHO 2000, 2002). Thus, scientifically sound arguments 
can be given to apply these TDI or PTMI values also for 
breastfed infant (Table 1).
Recently, the uptake via breastfeeding was estimated 
from 30 to more than 200 pg TEQ/kg bw per day (Li et al. 
2009) and our results are in line with these data. Therefore, 
it can be concluded that the WHO safety standards for DL 
compounds are exceeded with one to two orders of mag-
nitude during a period from several months to more than 
a year for the breastfed infant from all countries studied 
in these surveys (Figs. 3, 4). For PCBs as a group, the 
ATSDR minimum risk level (MRL) is 0.03 μg/kg bw per 
day (ATSDR 2000), and again our review indicates that this 
safety standard is exceeded by one to two orders of mag-
nitude for the countries included in these surveys (Fig. 5). 
Thus, in all countries studied, the levels in TEQs of DL 
compounds and ΣPCBs in human milk and its associated 
maternal body burden are still one to two orders of mag-
nitude above those considered toxicologically safe in early 
childhood.
Safety standards values have also been derived for DDT, 
and a provisional TDI of 10 μg/kg per day by the WHO 
was based on developmental toxicity in the rat (WHO 
2001). The US-EPA and ATSDR both derived a RfD and 
MRL of 0.5 μg/kg bw per day for acute and intermediate 
oral exposure situations (ATSDR 2004; US-EPA 2011). 
The levels of ΣDDTs are below or around those consid-
ered to be safe in the countries studied during these surveys 
Fig. 7  Relationships between PCDD, PCDF, PCB and DDT levels in pooled human milk samples from the WHO/UNEP surveys
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(Fig. 6) and from a toxicological point may be considered 
as acceptable in human milk.
Several epidemiological studies have focused on the 
risks of pre- and postnatal exposure to DL compounds, and 
effects on thyroid hormones, immunology, psychomotor 
and physical development have been observed in the breast-
fed infant. However, these effects were often transient and 
their clinical relevance discussed (Koopman-Esseboom 
et al. 1994, 1996; Pluim et al. 1993; Weisglas-Kuperus 
et al. 1995, 2000, 2004). Very recently, a study from Spain 
and Greece reported a negative relationship between 
maternal levels of DL compounds and anogenital distance 
in newborns (Vafeiadi et al. 2013). Many of these stud-
ies could not differentiate between possible effects of DL 
compounds (in TEQ) or PCBs due to their simultaneous 
occurrence in human milk. However, several studies pro-
vide evidence that prenatal exposure is more important than 
breastfeeding, which is in line with results from experimen-
tal studies with rodents and monkeys (Peterson et al. 1993). 
Taken together, it must be concluded that over the last two 
decades maternal body burdens of DL compounds and/or 
PCBs in industrialized countries, reflected in human milk 
levels, were still sufficiently high to cause subtle effects in 
the neonatal and early childhood period.
Human health effects of DDT and its metabolites have 
also been extensively studied, and adverse health effects 
in the neonatal period or early childhood have been impli-
cated (Eskenazi et al. 2009; WHO 2011). Again differentia-
tion between effects due to in utero versus neonatal expo-
sure is often not possible. Effects on thyroid hormones or 
growth in childhood or puberty have been reported, but 
results are not equivocal (Alvarez-Pedrerol et al. 2008; 
Asawasinsopon et al. 2006; Chevrier et al. 2008; Gladen 
et al. 2004; Karmaus et al. 2002; Rogan et al. 1987; Tak-
ser et al. 2005). These effects of DDT on thyroid hormones 
and body growth may well be transient, small and possibly 
not clinically relevant (Feeley and Brouwer 2000; Rogan 
et al. 1987).
More significant effects of DDT and/or DDE have been 
observed on neurocognitive and behavioral development 
that may persist into childhood (Darvill et al. 2000; Eske-
nazi et al. 2006; Gladen and Rogan 1991; Gladen et al. 
1988; Pan et al. 2010; Ribas-Fito et al. 2006; Rogan et al. 
1986; Torres-Sanchez et al. 2007). These effects are not 
consistent, but most indicate that the maternal body bur-
den and placental transfer are more important than breast-
feeding itself (Aliyu et al. 2010; Mead 2008). In addition, 
conflicting results have been obtained with respect to the 
transient nature of these cognitive developmental effects, 
but a prolonged effect into childhood cannot be excluded. 
In relation to this reduced cognitive or neurobehavioral 
development in breastfed infants, it must be recognized that 
experimental studies provide supporting evidence for such 
an effect (Arendt 2008).
Possible effects of DDT and/or DDE on the immune 
system have also been reported, but results are still incon-
clusive (Dallaire et al. 2004; Dewailly et al. 2000; Park 
et al. 2008; Sunyer et al. 2005). One study found a positive 
Fig. 8  Decline rates of PCDD, PCDF and PCB in some selected 
countries that have been studied during subsequent WHO/UNEP 
human milk survey periods (2000–2003 and 2005–2010)
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relationship between prenatal DDE exposure and infection 
rate, but a confounding role of DL compounds could not be 
excluded (Dallaire et al. 2004).
 Possible anti-androgenic effects after perinatal exposure 
to DDT and/or DDE in relation to hypospadias, anogenital 
distance and chryptochordism have also been studied (Bha-
tia et al. 2005; Brucker-Davis et al. 2008; Damgaard et al. 
2006; Flores-Luevano et al. 2003; Longnecker et al. 2002, 
2007). None of these studies provided conclusive evidence 
that pre- or postnatal exposure were associated with nega-
tive effects on the male development.
Benefits
Over the last decades, the benefits of breastfeeding for the 
infant and mother have been advocated extensively (Horta 
et al. 2007; James et al. 2009; WHO 2011). Thus, in any 
risk–benefit analysis the positive health effects of breast-
feeding must be balanced against possible adverse health 
effects of these POPs. A large number of neonatal studies 
established significant positive health aspects of breastfeed-
ing, but it is beyond the scope of our study to review all 
these studies in detail. In this review, we restrict ourselves 
to major outcomes and conclusions on this topic.
The most extensive and recent review on the posi-
tive health aspects of breastfeeding was done by the US 
Department of Health and Human Services, which included 
approximately 400 studies. It is concluded that breastfeed-
ing reduces a large variety of health problems in early 
childhood, including the risk of acute otitis media, non-
specific gastroenteritis, severe lower respiratory tract infec-
tions, atopic dermatitis, asthma (young children), obesity, 
possibly type 1 and 2 diabetes, childhood leukemia, SIDS 
and necrotizing enterocolitis (Ip et al. 2007). Quantifiable 
benefits of breastfeeding with respect to overall postnatal 
survival and hospitalization have also been reported, with 
a 30–40 % reduction in overall neonatal mortality and sud-
den infant death when breastfeeding. Furthermore, a longer 
Table 1  Different safety standards for dioxin-like compounds (TEQ) and DDT with calculated equivalent human milk levels
Information and formula used





[Safety standard(pg or µg/kg bw day)]
4.375 g lipid/kg bw day
Organization Safety standard Equivalent milk level Endpoint
PCDD/PCDF/PCB (TEQ) PCDD/PCDF/PCB (TEQ)
WHO (2000) TDI 1–4 pg/kg bw day 0.2–0.9 pg/g lipid Perinatal effects rodents and monkeys
US-EPA (2010) RfD (proposed) 0.7 pg/kg bw day 0.2 pg/g lipid Postnatal/childhood exposure humans
ATSDR (1998) MRL subchronic 1 pg/kg bw day 0.2 pg/g lipid Postnatal effect monkeys
Total PCBs Total PCBs
ATSDR (2004) MRL subchronic 0.03 μg/kg bw day 7 ng/g lipid Postnatal effect monkeys
DDT DDT
WHO (2001) TDI 10 μg/kg bw day 2300 ng/g lipid Developmental toxicity in rats
Table 2  General overview for the observed benefits of breastfeeding for the infant and mother (Ip et al. 2007; James et al. 2009)
Benefits for the infant
Optimal nutrition
Strong bonding with mother
Safe milk
Enhanced immune system
Reduced risk of acute otitis media, gastroenteritis, lower respiratory 
tract infections and asthma
Protection against allergies and intolerances
Correct development of jaw and teeth
Association with higher IQ/school performance
Reduced risk of chronic diseases, e.g., obesity, diabetes, heart disease, 
hypertension, hypercholesterolemia, childhood leukemia
Reduced risk of sudden infant death syndrome
Reduced risk of overall morbidity and mortality
Benefits for the mother
Strong bonding with infant
Increased energy expenditure, faster return to prepregnancy weight
Faster shrinking of the uterus
Reduced postpartum bleeding and delay menstrual cycle
Decreased risk of chronic diseases, e.g., breast and ovarian cancer, 
diabetes
Improved bone density, decreased risk hip fracture
Decreased risk postpartum depression
Enhanced self-esteem in the maternal role
Time and money saved from preparing and not buying formula, less 
medical expenses
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breastfeeding period was associated with a decreasing 
risk in health problems (Chen and Rogan 2004). A study 
from Spain indicated that 30 % of the neonatal hospital 
admissions could be avoided for every additional month 
of breastfeeding (Paricio Talayero et al. 2006). Thus, there 
is compelling evidence that breastfeeding is associated 
with a reduced mortality and morbidity with many benefi-
cial health effects for later life stages. In contrast, adverse 
health effects of POPs in human milk appear mostly tran-
sient in nature and less significant from a clinical point 
of view. The possible exception may be a reduced cogni-
tive performance that can persist in later life (Ribas-Fito 
et al. 2006). In Table 2, a general overview is given for the 
observed benefits of breastfeeding for the infant and mother 
(Ip et al. 2007; James et al. 2009).
Conclusions and future perspectives
Based on our present knowledge, we conclude that the bene-
fits of breastfeeding far outweigh the toxicological disadvan-
tages that are associated with certain POPs. Subtle adverse 
health effects of DL compounds for the fetus and infant 
can still be expected from prenatal exposure due to current 
maternal body burdens that can still be found in many coun-
tries around the globe. Experimental and epidemiological 
studies indicate that future risk–benefit assessments should 
focus more on the in utero situation, rather than on the 
breastfeeding period. Consequently, the risk–benefit debate 
of breastfeeding may well be redundant. The results of our 
global monitoring study indicate that recent human exposure 
to DL compounds and PCBs is still above those considered 
toxicologically safe for the fetus and breastfed infant, while 
those for DDT would be acceptable for the countries studied. 
Our observations provide a strong argument to plea for fur-
ther global source-directed measures to reduce human expo-
sure further to dioxin-like compounds.
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